Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate Cancer

Cabazitaxel will be administered IV on day 1 of each 21-day treatment cycle. Bavituximab (3 mg/kg) will be administered as an intravenous (IV) infusion on a weekly basis (Cycle 1 Day 2, all other cycles Day 1; day 8, day 15). Patients will receive cabazitaxel (day 1) plus bavituximab weekly of each 21-day cycle for up to 8 cycles. Up to 31 patients will be enrolled to ensure 28 evaluable subjects. The accrual period is expected to be between 12 to 18 months (1-1.5 years). Subjects will remain on the treatment phase of the study until any of the following events occur: * Disease progression as evidenced by an increase in the prostate-specific antigen (PSA) level, worsening of pain, or disease progression by Response Evaluation Criteria in Solid Tumors (RECIST) * Completion of 8 cycles of cabazitaxel-bavituximab therapy (day 169) * Development of toxicity that, in the investigator's judgment, precludes further study participation * Significant protocol violations or noncompliance on the part of the patient or investigator * The investigator's judgment that discontinuation is in the patient's best interest * Initiation of alternative antineoplastic treatments. * Refusal of the patient to continue treatment or follow-up * Loss to follow-up After completion of the treatment phase, subjects will remain on the followup phase of the study until any of the following events occur: * Refusal of the patient to continue treatment or follow-up * Loss to follow-up * Death * The investigator's judgment that discontinuation is in the patient's best interest